Last reviewed · How we verify
Meningococcal ACWY Conjugate Vaccine, MenACWY
Meningococcal ACWY Conjugate Vaccine, MenACWY is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Also known as: Menveo®.
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide capsules to a protein carrier.
MenACWY is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide capsules to a protein carrier. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | Meningococcal ACWY Conjugate Vaccine, MenACWY |
|---|---|
| Also known as | Menveo® |
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polysaccharide capsules from Neisseria meningitidis serogroups A, C, W, and Y conjugated to a diphtheria toxoid protein carrier. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, leading to robust production of bactericidal antibodies that protect against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults (PHASE3)
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (PHASE3)
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (PHASE3)
- Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study
- A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age (PHASE2)
- A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age (PHASE2)
- A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal ACWY Conjugate Vaccine, MenACWY CI brief — competitive landscape report
- Meningococcal ACWY Conjugate Vaccine, MenACWY updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Meningococcal ACWY Conjugate Vaccine, MenACWY
What is Meningococcal ACWY Conjugate Vaccine, MenACWY?
How does Meningococcal ACWY Conjugate Vaccine, MenACWY work?
What is Meningococcal ACWY Conjugate Vaccine, MenACWY used for?
Who makes Meningococcal ACWY Conjugate Vaccine, MenACWY?
Is Meningococcal ACWY Conjugate Vaccine, MenACWY also known as anything else?
What drug class is Meningococcal ACWY Conjugate Vaccine, MenACWY in?
What development phase is Meningococcal ACWY Conjugate Vaccine, MenACWY in?
What are the side effects of Meningococcal ACWY Conjugate Vaccine, MenACWY?
What does Meningococcal ACWY Conjugate Vaccine, MenACWY target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
- Also known as: Menveo®
- Compare: Meningococcal ACWY Conjugate Vaccine, MenACWY vs similar drugs
- Pricing: Meningococcal ACWY Conjugate Vaccine, MenACWY cost, discount & access